Lineage Cell Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.03 | $-0.03 | +0.0% | Beat |
| Q12026 FY2026 | $-0.02 | $-0.03 | -50.0% | Miss |
| Q42025 FY2025 | $-0.07 | $0.00 | +100.0% | Beat |
Back to LCTX overview · LCTX holders · LCTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.